SLC5A2 and hydrops fetalis: Meta-analyses of clinical trials underscore the potential impact of SGLT2 inhibitors on SCD and cardiac arrhythmias, including ventricular arrhythmias (VAs) across various patient categories, including HF, diabetes and CKD [99–101].